Barriers to Diversity In Clinical Trials

BARRIERS AFFECTING ENROLLMENT

- Unconscious Bias
 - Staff training to identify and correct bias tendencies
- Mistrust/Historical Discrimination

 - Community- Ambassadors (community laypeople) to increase trial awareness Workforce-training to better communicate CT opportunities (videos, education level, cultural specifics),
 - Increase diversity in workforce
- Location- clinical trials not available where their care is given
 - Creating research collaborations with researchers, community based organizations and community cancer centers to bring trials to community centers
 - Infrastructure built for information sharing (both ways)
- Inclusion/Exclusion Criteria
 - Minimum enrollment requirements
 - Broaden eligibility criteria
 - Intentional enrollment of underrepresented populations
- Cultural Competence-Understanding and respect of the diversity of a population (Language, communication) styles, beliefs, attitudes, behaviors)
 - Increase diversity in workforce staff that shares cultural characteristics with the patients

Barriers to Diversity In Clinical Trials

- Language
 - Consent language difficult to understand
 - Trial materials not offered in the native language
 - Translating consent forms can be costly and not covered by research budgets
 - Provide translated materials and even better to have access to in person/phone translation assistance
- Financial Challenges -(Cost of Participating in a clinical trial)
 Medical costs ACCESS
 - - Cover Routine care costs if denied by insurance OR
 - Clinical Trial Coverage Act (everyone should support this:
 Introduced by Jackie Speier (SB37); now Anna Eshoo
 - Non-Medical Costs (Out of pocket costs)
 - Cost of Transportation
 - Cost of dependent and/or childcare
 - Lodging/meals
 - Standardize reimbursement for out-of-pocket costs, assist arranging
 - travel and parking
 - days off work
 - dependent care
- Logistical Challenges (Indirect costs for patients)
 - Time commitment and dependent care
 - Can be offset by telemedicine for routine visits, shipping oral study medications to patients, using local clinics and imaging for certain activities. (Implemented during COVID)

I-SPY ACCESS

Achieving Cancer **Clinical Trial Equity through** Socioeconomically diverse Sites

Sites Supporting Under-Represented Populations

- Hospitals associated with HBCUs
- Sites treating primarily Black, Hispanic/Spanish speaking, Asian and Native American patients
- Safety net hospitals/County hospitals
- Community Cancer Centers
- Rural Cancer centers

Understanding the Unique Facilitators and Barriers that Influence Clinical Trial Enrollment

Dominic Zavala
Program Coordinator at USC,
MHA Candidate at UCLA



Project Background



Problem: Increased difficulty enrolling diverse ethnic groups into clinical trials within the breast oncology clinic at Los Angeles General



Project: Understand the unique facilitators and barriers that influence patient enrollment at the LAG breast clinic



Ideal setting: LA County is the most populous and diverse county in the U.S.

Methods

REDCap Database

Record ID	Demographics	Income	Birthplace		Current Address	Employment Status		English Proficiency	Race Ethnicity				Clinical Trial Reassessment		
3	0	0	0	0	0	0	0	0	0	0	0	0	0	•	
4	0	0	0	0	0	0	0	0	0	9	0	0	0	•	
5		0	0	0	0	0	0	0	0	0	0	0	0	0	
6		0	0	0	0	0	0	0	0	0	0	0	0		
7	•	0	0	0	0	0	0	9	0	0	0	0		•	
8	•	0	0	0	0	0	0	0	0	0	9	0	0		
9	•	0	0	0	0	0	0	0	0	0	0	0		0	
10	•	0	0	0	0	0	0	0	0	0	0	0	0		
<u>11</u>	•	0	0	0	0	0	0	0	0	0	0	0		•	
<u>12</u>	•	0	0	0	0	0	0	0	0	0	0	0	0		
<u>13</u>	•	0	0	0	0	0	0	0	0	0	0	0			
14		0	0	0	0	0	0	0	0	0	0	0	0	0	
<u>15</u>	•	0	0	0	0	0	0	0	0	0	0	0	•	•	
<u>16</u>		0	0	0	0	0	0	0	0	0	0	0	0	0	
17	•	0	0	0	0	0	0	0	0	0	0	0	•	0	
18		0	0	0	0	0	0	0	0	0	0	0			•
19	•	0	0	0	0	0	0	0	0	0	0	0		0	
20		0	0	0	0	0	0	0	0	0	0	0		0	•




Survey Example

Awareness and Un	Inderstanding
How familiar are you with clinical trials for breast cancer?	Very familiar somewhat Neutral Not very Not at all
How well do you understand the purpose and procedures in clinical trials?	Vory well Well Not well Not well Not at all
Interest and W	
How interested are you in participating in a breast cancer clinical trial?	Very interested interested Neutral Not very interested Not interested at all
Vould you consider participating in a breast cancer clinical trial frecommended by your healthcare provider?	Definitely Yes Probably Yes Not sure Probably No Definitely No
Motivation	
What motivates you to consider participating in a breast cancer clinical trial?	Access to new treatments Contribute to scientific research Support for future patients Recommended by healthcare providers Other
Concerns and	d Barriers
What concerns do you have about participating in a breast cancer clinical trial? (Select all that apply)	Potential side effects Time commitment Travel and Logistic Uncertainty of effectiveness Impact on quality of life Costs and insurance coverage Other (please specify)
How likely are concerns about side effects to affect your decisions to participate in a clinical trial?	Very likely Likely Current Current Unlikely res


Preliminary Result

Pre-Intervention




Preliminary Results

Participation if Recommended by Healthcare Provider



Participation if Recommended by Healthcare Provider



Future Goals

Integrate additional surveys

Continue data collection

Resource allocation


Provide recommendations

Thank You

Financial
Barriers and
Insurance
Coverage in
Clinical Trials

MODERATOR: KIM RHOADS





Racial/ethnic diversity is historically low in cancer clinical trials nationally






Addressing low representation in clinical trials requires transformational change

Methods

- Meta analysis
- ■N=13 trials included
- N=8800 US patients

Magnitude of structural, clinical & physician and patient barriers to participation (Unger, et al. JNCI 2019)

UCSF Helen Diller Family
Comprehensive
Cancer Center



"After all is said and done, a lot more is said than done"

--ARNOLD PERKINS, FOUNDING MEMBER, AND RECENT PAST CHAIR, HDFCCC COMMUNITY ADVISORY BOARD (2005-2023)





Editorial: Who should fund much needed change?

Stakeholder	Incentive	Description of work	
Patients	Better outcomes	Transportation, clinical companionship, childcare	
Non-Profit Orgs	Addressing inequity	Community engagement & navigation & training, Transportation, clinical advocacy, childcare, addressing financial toxicity, food and housing needs	
Cancer Centers & Clinics	Better science/results	Cultural Competence training and??	
Pharma	Reputation & Future Sales	Funding trials; smaller funding support for community engagement and navigation	